Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients With Metastatic Gastroesophageal Adenocarcinoma.

Trial Profile

Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients With Metastatic Gastroesophageal Adenocarcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Everolimus (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 10 Feb 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017, according to ClinicalTrials.gov record.
    • 12 Aug 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top